undamentalytics Newsletter
Sign in

PMV Pharmaceuticals, Inc. (PMVP) stock

Add to watchlist

Add holding +

NASDAQ: PMVP Nasdaq Biotechnology Next results ~November 16, 2026

PMV Pharmaceuticals, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds19 adding, 30 cuttingOf 11 active managers that changed their stake, 5 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 16, 2026 (estimated)

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 15% in the quarter to 2026-06-30, the 4th beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Results due soon. Results are expected around 11 November; the share price can move sharply on the day.
  • Volatile shares. Over the past year the shares showed annualised volatility of 72% and a beta of 0.8 against the S&P 500.

Latest results

Earnings per share
-$0.34 against an average estimate of -$0.40: beat by 15.0%
Share reaction
+2.9% in the first session after the results on August 14, 2026, against -0.7% for the S&P 500
Next report
November 16, 2026; average EPS estimate -$0.34

PMV Pharmaceuticals' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+4.6%
  • 1 week+21.2%
  • 1 month-23.5%
  • This year+9.6%
  • 1 year-2.8%
  • 5 years-94.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 14, 2026
Next results (est.)
November 11, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Agreement
  3. Announcement
  4. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

PMV Pharmaceuticals, Inc. valuation models and calculator

No model value for PMV Pharmaceuticals, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 16, 2026, before the open. Analysts expect revenue of $0 and EPS of −$0.34 (range −$0.41 to −$0.25) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.28 +13% — 0%
Next −$0.97 +25% $5m 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −15.3% on 90 days ago. In the last 30 days, 2 analysts raised PMV Pharmaceuticals, Inc.'s forecast and 0 cut it.

Consensus EPS forecast PMV Pharmaceuticals, Inc., last 90 days
−$2.00 −$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.51 Current fiscal year, 60 days ago: −$1.51 Current fiscal year, 30 days ago: −$1.51 Current fiscal year, 7 days ago: −$1.41 Current fiscal year, Now: −$1.28 −$1.28 Next fiscal year, 90 days ago: −$1.09 Next fiscal year, 60 days ago: −$1.09 Next fiscal year, 30 days ago: −$1.09 Next fiscal year, 7 days ago: −$1.15 Next fiscal year, Now: −$0.97 −$0.97

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.51−$1.09
60 days ago −$1.51−$1.09
30 days ago −$1.51−$1.09
7 days ago −$1.41−$1.15
Now −$1.28−$0.97

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.40 −$0.34 +15.0%
Mar 2026 −$0.39 −$0.34 +11.7%
Dec 2025 −$0.40 −$0.34 +13.9%
Sept 2025 −$0.40 −$0.40 +0.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

6 analysts, Oct 2026
Buy6100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202666
  2. Sep 202655
  3. Aug 202655

Counts of recommendations published by analysts covering PMV Pharmaceuticals, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
3.1%
of tradable shares
Days to cover
2.59
at average volume
Short interest, 1 month
−22%
to October 15, 2026
Held by institutions
46%
of shares
Held by insiders
2.4%
of shares
Employees
54
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
PMVP−62%−62%−64%−51%−17%+10%
Industry peers (median)−35%−56%−17%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
PMVP33%33%50%42%25%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
PMVP−68%−65%−87%−54%−47%−42%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since September 25, 2020: 99% from December 31, 2020 to May 15, 2025. Getting back needed a 7240% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.02 – $1.80
From 52-week high
−23.9%
vs 50-day average
−1.0%
vs 200-day average
+5.2%
Volatility (1 year)
72%
Beta vs S&P 500
0.76

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±4.4%
After a week
7 up, 5 down
typical move ±5.9%
After a month
4 up, 8 down
typical move ±14.8%
Results releasedNext dayS&P 500 next day5 days21 days
August 14, 2026 +2.9% −0.7% +9.5% +11.9%
May 12, 2026 −7.2% +0.4% −5.8% −21.6%
March 6, 2026 +6.5% −0.4% +2.0% −15.7%
November 12, 2025 +2.3% −1.6% +2.3% −7.5%
August 7, 2025 −2.6% +0.7% +2.0% −7.9%
May 9, 2025 −2.3% +3.2% −2.0% +34.6%
March 3, 2025 −5.8% −2.9% −10.9% −26.3%
November 7, 2024 +4.8% +1.2% −3.6% −4.2%
August 8, 2024 −1.4% +2.8% +5.5% +4.1%
May 9, 2024 −5.6% +0.7% −0.5% −21.3%
February 29, 2024 +3.6% +1.3% +2.8% −1.7%
November 9, 2023 +7.5% +0.8% +23.7% +21.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$46.4M
Institutions reporting
63
Shares held vs prior quarter
▼ 6.4%
Positions opened / closed
4 / 10

Top buyers and sellers, Q2 2026: 19 institutions bought and 30 sold ; the biggest buyer was Adage Capital Partners Gp, L.L.C (+500K shares) and the biggest seller Arrowmark Colorado Holdings LLC (−913K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Bml Capital Management, LLC $7.1M 5.3M 15.4% ▲ 0.2%
Tang Capital Management LLC $5.7M 4.2M 12.3% 0.0%
Sio Capital Management, LLC $3.5M 2.6M 7.6% ▼ 14.4%
Euclidean Capital LLC $3.5M 2.6M 7.6% 0.0%
Adage Capital Partners Gp, L.L.C. $3.2M 2.4M 6.8% ▲ 26.9%
Acadian Asset Management LLC $3M 2.2M 6.4% 0.0%
Vanguard Capital Management LLC $2.7M 2.0M 5.8% ▲ 1.9%
Arrowmark Colorado Holdings LLC $2.6M 2.0M 5.7% ▼ 31.8%
Two Sigma Investments, LP $2.6M 2.0M 5.6% ▲ 3.7%
Eversept Partners, LP $2.5M 1.9M 5.5% ▼ 19.5%
Blackrock, Inc. $1.2M 920K 2.7% ▲ 5.2%
Assenagon Asset Management S.A. $884,408 660K 1.9% ▲ 82.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not PMV Pharmaceuticals, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 11, 2026 estimated from the company's past filing pattern, not announced

  • August 14, 2026
  • May 12, 2026
  • March 6, 2026
  • November 12, 2025
  • August 7, 2025
  • May 9, 2025

Recent SEC filings

Data status

When each part of this page on PMV Pharmaceuticals, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

PMV Pharmaceuticals, Inc. in brief

What does PMV Pharmaceuticals, Inc. do?
PMV Pharmaceuticals, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is PMV Pharmaceuticals, Inc.'s stock ticker?
PMV Pharmaceuticals, Inc. trades under the ticker PMVP on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are PMV Pharmaceuticals, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Bml Capital Management, LLC, Tang Capital Management LLC and Sio Capital Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
When is PMV Pharmaceuticals, Inc.'s next earnings date?
Around November 16, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — PMV Pharmaceuticals, Inc. announces its own schedule.